Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
11:05am, Tuesday, 30'th Apr 2024
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mahesh Krishnan Elected to Halozyme's Board of Directors
04:45pm, Thursday, 25'th Apr 2024
SAN DIEGO , April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors.
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
06:00am, Thursday, 25'th Apr 2024
If you have a high tolerance for volatility then the biotech sector might be for you. Biotech stocks can range from pre-revenue startups to global pharmaceutical giants.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
10:51am, Wednesday, 24'th Apr 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme to Report First Quarter 2024 Financial and Operating Results
08:30am, Tuesday, 23'rd Apr 2024
SAN DIEGO , April 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, Ma
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Thursday, 18'th Apr 2024
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 18'th Apr 2024
Halozyme Therapeutics (HALO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Thursday, 04'th Apr 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The 3 Best Biotech Stocks to Buy in Q2 2024
06:40am, Friday, 29'th Mar 2024
Biotech is an industry full of opportunity. It's also known as one of the riskiest sectors to invest in.
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
12:36pm, Thursday, 21'st Mar 2024
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:41am, Tuesday, 19'th Mar 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
02:25pm, Wednesday, 13'th Mar 2024
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno
Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag
12:31pm, Wednesday, 21'st Feb 2024
Halozyme's (HALO) fourth-quarter 2023 earnings meet estimates, while revenues miss the same.
Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics
06:30pm, Tuesday, 20'th Feb 2024
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wal
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
06:11pm, Tuesday, 20'th Feb 2024
Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.82 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.48 per share a year ago.
